Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment [0.03%]
初始治疗后高危生化复发的流行病学研究
Ugo Giovanni Falagario,Francesco Pellegrino,Lars Björnebo et al.
Ugo Giovanni Falagario et al.
Background and objective: Biochemical recurrence (BCR) risk stratification guides treatment decisions after primary prostate cancer (PCa) treatment. We evaluated high-risk BCR (HR-BCR) definitions after radical prostatect...
Prostate Cancer Testing Between Screening Rounds: Evidence from the STHLM3-MRI Trial [0.03%]
STHLM3-MRI试验间期前列腺癌筛查的证据分析
Daniela Skalt,Ting Chen,Ahmad Abbadi et al.
Daniela Skalt et al.
Background and objective: The STHLM3-MRI screening-by-invitation trial found that magnetic resonance imaging (MRI)-based screening for prostate cancer (PCa) improved early detection in comparison to systematic biopsy. The...
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy [0.03%]
SOLAR和SATURN临床试验的汇总分析：系统治疗和肿瘤定向治疗后同步与异步前列腺特异性膜抗原定义的寡转移性前列腺癌的进展比较
Jesus E Juarez Casillas,John Nikitas,Matthew B Rettig et al.
Jesus E Juarez Casillas et al.
Multimodal strategies combining primary and metastasis-directed therapy (MDT) with short-term intensified systemic therapy may improve outcomes in oligometastatic castrate-sensitive prostate cancer (omCSPC) while minimizing long-term toxici...
Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, and Rodolfo Montironi's Letter to the Editor re: Francesca Ambrosini, Nataniele Piol, Matteo Bauckneht, et al. Immunohistochemical Prostate-specific Membrane Antigen (PSMA) Expression Patterns of Primary Prostate Cancer Tissue as a Determining Factor for Prostate Cancer Staging wi [0.03%]
关于Alessia Cimadamore，Antonio Lopez-Beltran，Liang Cheng和Rodolfo Montironi致编辑部的信：Francesca Ambrosini，Nataniele Piol，Matteo Bauckneht等原发前列腺癌活检组织免疫组化前列腺特异性膜抗原（PSMA）表达模式作为前列腺癌分期决定因素的来信回复
Francesca Ambrosini,Nataniele Piol,Matteo Bauckneht et al.
Francesca Ambrosini et al.
Prostate Cancer Outcomes in Immunocompromised Patients: A Systematic Review and Meta-analysis [0.03%]
免疫功能低下患者前列腺癌预后的系统评价和meta分析
Francesco Sanguedolce,Alessandro Tedde,Giuseppe Basile et al.
Francesco Sanguedolce et al.
Background and objective: The role of immunosuppression in prostate cancer (PCa) mortality is a debated topic, with a low level of evidence. This review aims to evaluate the cancer-specific mortality (CSM) and overall mor...
Propensity-matched Comparison of Single-port Transvesical Versus Standard Multiport Robotic Radical Prostatectomy [0.03%]
单孔与多孔机器人辅助根治性前列腺切除术的倾向匹配分析
Nicolas A Soputro,Carter D Mikesell,Salim K Younis et al.
Nicolas A Soputro et al.
Background and objective: Introduction of the purpose-built single-port (SP) robotic platform has paved the ways for the advent of novel, regionalized surgical techniques for robot-assisted radical prostatectomy (RARP), i...
Stereotactic Body Radiation Therapy for Primary Renal Cancer and Genetic Markers of Response: A Phase 2 Trial [0.03%]
立体定向身体放射治疗原发性肾癌及反应的遗传标志物：一项二期临床试验
Cheryn Song,Chang Ohk Sung,Dongsu Kim et al.
Cheryn Song et al.
Controlled outcome assessment of radiotherapy for primary renal cell carcinoma (RCC) remains limited, particularly regarding its impact on ipsilateral renal function and predictors of response. We evaluated oncological and renal function ou...
Real-World Experience with a Commercial Circulating Tumor DNA Assay in Non-muscle-invasive Bladder Cancer [0.03%]
商业循环肿瘤DNA检测在非肌层浸润性膀胱尿路上皮癌中的实际应用体验
Betty Wang,Laura E Davis,Christopher J Weight et al.
Betty Wang et al.
Circulating tumor DNA (ctDNA) is an emerging biomarker in advanced bladder cancer, but its role in non-muscle-invasive bladder cancer (NMIBC) remains undefined. We conducted a retrospective study of 23 patients with NMIBC who underwent seri...
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial [0.03%]
初始转移性前列腺癌联合细胞减灭术、放疗或消融的IP2-ATLANTA内部预试验二期随机对照试验
Martin J Connor,Taimur T Shah,Johanna Sukumar et al.
Martin J Connor et al.
Background and objective: Cytoreduction of the primary prostate cancer, involved lymph nodes, and metastases may confer improved cancer control in de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC). ...
Clinical Trial Protocol: Impact of Testosterone Replacement Therapy on Functional and Oncological Outcomes Following Radical Prostatectomy (ENFORCE Study) [0.03%]
术后睾酮替代治疗对根治性前列腺切除术功能和肿瘤结局影响的临床试验方案（ENFORCE研究）
Diederik Baas,Joost van Drumpt,Lambertus Kiemeney et al.
Diederik Baas et al.
Background and objective: Testosterone deficiency (TD) affects 18-38% of men undergoing radical prostatectomy (RP) for localised prostate cancer and may impair postoperative sexual rehabilitation. Testosterone replacement...